<DOC>
	<DOCNO>NCT01093066</DOCNO>
	<brief_summary>Radical cystectomy treatment choice bladder infiltrative urothelium carcinoma . But removal bladder reservoir major impact Quality life . Neoadjuvant chemotherapy show associated absolute 5 % survival benefit . Two monocentric study suggest neoadjuvant chemotherapy could use combination optimal transurethral bladder resection , strategy bladder preservation , provide complete response obtain ( 50 % every trial use neoadjuvant MVAC protocol radical cystectomy ) . In study patient T2 T4 , 5 year overall survival 65 % , 40 % bladder preservation rate 5 year . The feasibility efficacy attitude multicentric trail use active regimen ( term complete response metastatic patient ) unknown . The chosen regimen therefore intensify MVAC allows , use G-CSF , double dose-intensity Adriamycin Cisplatinum , decrease 30 % methotrexate vinblastine dose-intensity . The efficacy safety confirmation approach could lead consider patient motivate retain functional bladder .</brief_summary>
	<brief_title>Prospective Multicentric Evaluation Bladder Preservation Strategy</brief_title>
	<detailed_description>Every patient sign inform consent follow step Maximal optimal TURB use standardized procedure . The TURB always try optically complete . Neoadjuvant chemotherapy 3 month intensify MVAC ( 6 cycle administer every 2 week ) : METHOREXATE : 30 mg/m2 D1 - VINBLASTINE : 3 mg/m2 D2 - ADRIAMYCINE 30 mg/m2 D2 - CISPLATINE 70 mg/m2 D2 . + G-CSF : 5 µg/kg D4 D10 New maximal standardize TURB end chemotherapy . In case lesion localize bladder dome , maximal TURB appear unsafe , partial cystectomy without lymph node dissection perform . If complete response obtain ( tumor cell bladder muscle last TURB ) , surveillance propose without treatment . Otherwise ( tumor cell bladder muscle second TURB ) , radical cystectomy do . If balder spar , follow follow : clinical examination , CT , bladder endoscopy urinary cytology every 6 month . The possible non muscle infiltrative bladder relapse treat accord</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<criteria>T2 clinical stage ( palpable mass anesthesia TURB ) Absence diffuse Cis ( Cis random bladder biopsy ) Patients 18 , 70 year age PS status ≤ 2 No previous treatment bladder muscle infiltrative carcinoma . Previous endovesical instillation non muscle infiltrative lesion ( pTa , pT1 , Cis ) allow . No metastasis tauracoabdominapelvic CT scan ( node &gt; 1 cm ) bone scan . Normal biological value : neutrophil &gt; 1,5.109 /l , platelet &gt; 100 . 109 /l , Alkaline Phosphatases &lt; 2 x N , bilirubin &lt; 1,5 N , Transaminases &lt; 1,5 x N , Creatinine clearance ≥ 60 ml/min Signed inform consent Patient belong social security system . All histology urothelial carcinoma : primitive adenocarcinoma epidermoid carcinoma little cell carcinoma In situ diffuse carcinoma associate urothelial carcinoma muscular infiltrate Tumor stade &gt; T2 , T3 T4 pT4a ( prostatitis ) Serious cardiac , pulmonary , hepatitic , renal , digestive neurological pathology non equilibrate potential aggravating risk treatment Cancer history actual cancer ( except skin cancer ) remission end treatment inferior 2 year Participation another clinical trial delay inferior 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>urothelial carcinoma</keyword>
	<keyword>TURB</keyword>
	<keyword>chemotherapy</keyword>
</DOC>